DEXA Scan for Visceral Fat: What to Expect

A DEXA scan for visceral fat offers one of the most detailed, non-invasive ways to measure the metabolically active fat stored deep within the abdominal cavity. Unlike BMI or waist measurements, DEXA uses dual-energy X-ray absorptiometry to distinguish visceral adipose tissue from subcutaneous fat, providing clinically meaningful data on cardiometabolic risk. This article explains how the scan works, how accurate it is, who should consider one in the UK, what the results mean, what it costs privately, and how follow-up scans can track progress when reducing visceral fat.

What is a DEXA scan and how does it measure visceral fat?

A DEXA scan measures visceral fat by using two low-dose X-ray beams to distinguish bone, lean tissue and fat, including deep abdominal visceral adipose tissue around the organs. The painless 10 to 20 minute procedure requires no injections and delivers a lower radiation dose than a standard abdominal CT scan.

A DEXA (dual-energy X-ray absorptiometry) scan measures visceral fat by using two low-dose X-ray beams at different energy levels to distinguish between bone mineral, lean tissue and fat tissue throughout the body, including the fat stored deep within the abdominal cavity around the organs. Originally developed to assess bone density, modern DEXA software now produces detailed body composition reports that separate subcutaneous fat (the fat just beneath the skin) from visceral adipose tissue (VAT), which is the metabolically active fat surrounding the liver, pancreas and intestines.

During the scan, you lie flat on a padded table while a scanning arm passes slowly over your body. The procedure is painless, requires no injections or contrast agents, and typically takes between 10 and 20 minutes. Because DEXA uses ionising radiation, you should inform the clinic if you are pregnant or think you could be pregnant; non-urgent scans should be postponed in that situation. The radiation dose from a whole-body DEXA scan is low and considerably less than that from a standard abdominal CT scan, though the precise effective dose varies by scanner model and protocol.

The DEXA software estimates visceral fat by analysing the abdominal region and applying validated algorithms to separate the two fat compartments.^[9][10] The metrics reported, which may include visceral fat area in square centimetres, visceral fat mass in grams or kilograms, or a percentile ranking against a reference population, vary depending on the scanner manufacturer and software version. Not all providers report all of these metrics, so it is worth confirming with your clinic what their report includes. This level of detail is not available from simple waist measurements or body mass index (BMI) calculations, which is why DEXA is increasingly used in both clinical research and private health screening.

How accurate is a DEXA scan compared to other body fat tests?

DEXA is more accurate than bioelectrical impedance, waist circumference or BMI for estimating visceral fat, though MRI and CT are the most precise reference methods. Its main limitation is variability between scanner manufacturers, so serial scans are most reliable when performed on the same machine.

DEXA is widely regarded as one of the most accurate non-invasive methods for estimating visceral fat, though MRI and CT scanning remain the gold-standard reference techniques used in research settings.^[9] Studies comparing DEXA-derived visceral fat estimates against CT measurements have generally found strong correlations, with DEXA performing considerably better than waist circumference, BMI, bioelectrical impedance analysis (BIA) or skinfold callipers for quantifying visceral adiposity.^[9][10]

Each method has its limitations. CT and MRI provide direct cross-sectional images of abdominal fat compartments and are the most precise, but CT carries a higher radiation dose and both are expensive and less accessible. BIA devices, including consumer smart scales, estimate total body fat using electrical resistance but cannot reliably distinguish visceral from subcutaneous fat, and results vary significantly with hydration status. Waist circumference is a useful population-level screening tool included in NICE guidance on obesity and cardiovascular risk assessment, but it cannot separate the two fat compartments in an individual.^[6]

DEXA sits in a practical middle ground: more accurate than BIA or anthropometric measures, less invasive and less costly than MRI, and delivering a lower radiation dose than CT. Its main limitations include variability between different scanner manufacturers and software versions, meaning that serial measurements are most meaningful when performed on the same machine using the same software. Hydration status and recent food intake can also introduce small errors, so attending under similar conditions each time improves comparability. For most people seeking a detailed, reproducible body composition assessment outside a research setting, DEXA currently offers a reasonable balance of accuracy, safety and accessibility.

Who should consider getting a DEXA scan in the UK?

People with metabolic risk factors, a normal BMI but excess abdominal fat, or South Asian, East Asian or Black African heritage are among those most likely to benefit from a DEXA visceral fat assessment. Body composition DEXA is not routinely available on the NHS and is accessed privately, with all exposures requiring justification under IR(ME)R.

People who have a normal or near-normal BMI but carry excess abdominal fat, or those with metabolic risk factors such as raised blood glucose, high triglycerides or elevated blood pressure, are among those most likely to benefit from a DEXA scan for visceral fat assessment. BMI alone can be misleading: individuals classified as a healthy weight can still carry clinically significant levels of visceral fat, a pattern sometimes described as metabolically obese normal weight (MONW), while people with a higher BMI may have a relatively favourable fat distribution.

Other groups who may find a DEXA scan informative include:

• People with a family history of type 2 diabetes, cardiovascular disease or non-alcoholic fatty liver disease

• Those who have experienced significant weight changes and want to understand whether they have lost fat or lean muscle mass

• Individuals considering or already using weight-management treatments who want an objective baseline and follow-up measure

• People of South Asian, East Asian or Black African heritage, who are recognised in NICE guidance as carrying higher cardiometabolic risk at lower BMI thresholds, and who may benefit from earlier assessment of visceral adiposity^[7][8]

• Athletes or people who exercise regularly and want to assess body composition beyond weight alone

Because DEXA uses ionising radiation, exposures must be justified by an entitled practitioner under the Ionising Radiation (Medical Exposure) Regulations (IR(ME)R).^[5] Many private providers accept self-referrals but will ask for relevant clinical information to complete this justification process. Always inform the clinic if you are pregnant or think you could be pregnant before booking.

DEXA scanning for body composition is not currently commissioned as a routine NHS investigation for visceral fat in otherwise healthy adults. It is available privately at a range of clinics and imaging centres across the UK. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician can advise whether a body composition assessment is appropriate for your circumstances. Discussing your results with a GP or qualified clinician after the scan is strongly recommended.

What do your DEXA scan results actually mean for your health?

High visceral fat on DEXA is independently associated with increased risk of type 2 diabetes, cardiovascular disease and MASLD, and warrants clinical review alongside blood pressure, fasting glucose, HbA1c and lipid profile. Results should be discussed with a GP, who can assess overall cardiovascular risk using tools such as QRISK3.

Elevated visceral fat on a DEXA scan is associated with an increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease or NAFLD) and certain cancers, independent of total body weight. Visceral adipose tissue is metabolically active, releasing inflammatory cytokines and free fatty acids that can impair insulin signalling, raise blood lipids and promote arterial inflammation.^[11][12] This is why two people with identical BMI values can have very different cardiometabolic risk profiles depending on where their fat is stored.

DEXA reports typically present visceral fat as a mass or area alongside a percentile ranking, though the exact metrics depend on the scanner and software used. A result in a high percentile for your age and sex group suggests a greater degree of visceral adiposity relative to your peers and warrants discussion with a clinician. There are no universally accepted risk thresholds for DEXA-reported VAT metrics that apply across all populations and platforms, so results should always be interpreted alongside other clinical information such as blood pressure, fasting glucose, HbA1c, lipid profile and waist circumference.

The scan also provides data on lean muscle mass, which is clinically relevant. Low muscle mass (sarcopenia) combined with high fat mass (sarcopenic obesity) carries a particularly unfavourable metabolic and functional prognosis.^[21][22] Understanding both components helps clinicians and patients make more targeted decisions about diet, physical activity and, where appropriate, medical treatment.

If your results indicate high visceral fat, your GP can arrange relevant blood tests and assess your overall cardiovascular risk using validated tools such as QRISK3, which is recommended by NICE for primary prevention of cardiovascular disease in adults.^[13]

How much does a DEXA scan cost privately in the UK?

Private DEXA body composition scans vary in price across the UK depending on provider, location and whether a clinical consultation is included; costs are higher in London and major cities. Body composition scanning for visceral fat is not NHS-funded and must be paid for privately, unlike bone density scans which may be available on the NHS.

Private DEXA body composition scans in the UK vary considerably in price depending on the provider, location and whether the scan includes a detailed consultation to interpret the results. Prices in London and other major cities tend to be higher than in other regions, and packages that combine a DEXA scan with blood tests, fitness assessments or dietitian consultations will affect the overall cost. It is advisable to check current pricing directly with providers, as costs change over time.

It is important to distinguish between a body composition DEXA scan and a bone density (DEXA) scan. Bone density scans are sometimes available on the NHS for people at risk of osteoporosis, following NICE guidance, but body composition scanning for visceral fat assessment is not routinely funded by the NHS and must be paid for privately.^[3][24] The two scans use the same technology but different software protocols and produce different reports.

When comparing providers, consider the following:

• Whether the price includes a written report with visceral fat data specifically, not just total body fat percentage

• Whether a clinician or qualified health professional reviews and explains the results

• The scanner manufacturer and software version, as consistency matters if you plan repeat scans

• Whether the facility complies with IR(ME)R and has appropriately trained radiographers or technologists with clinical oversight for justification and reporting

• Whether the facility is registered with the relevant regulator: the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS), Healthcare Inspectorate Wales (HIW), or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland

A scan without professional interpretation of the results has limited clinical value.

Can you reduce visceral fat and how would a follow-up scan show progress?

Visceral fat responds to sustained calorie deficit, aerobic exercise, resistance training and, where eligible, MHRA-authorised pharmacological treatments such as GLP-1 receptor agonists. A follow-up DEXA scan on the same machine after three to six months can objectively quantify changes in visceral fat and distinguish fat loss from lean muscle loss.

Visceral fat is responsive to lifestyle change and, where clinically appropriate, medical treatment, making it one of the more modifiable cardiovascular risk factors. A sustained calorie deficit achieved through dietary change, increased physical activity or a combination of both is the foundation of visceral fat reduction. Evidence consistently shows that aerobic exercise, resistance training and dietary approaches that reduce overall energy intake can all reduce visceral adiposity, often before significant changes in total body weight become apparent.^[14][15]

For people with obesity and related metabolic conditions, NICE-recommended weight-management interventions, including structured behavioural programmes and, where eligible, pharmacological treatment, have been shown to reduce visceral fat alongside total body weight. GLP-1 receptor agonists and dual GIP and GLP-1 receptor agonists, which are MHRA-authorised for chronic weight management in eligible adults, have demonstrated reductions in visceral fat in clinical trials.^[18][19] These medicines work by reducing appetite and slowing gastric emptying, leading to a sustained reduction in calorie intake. A prescriber can advise whether any of these treatments may be appropriate following a clinical assessment.

A follow-up DEXA scan, ideally performed on the same machine and under similar conditions (similar hydration, time of day and fasting status), can objectively quantify changes in visceral fat mass over time. Repeat scans should be clinically justified in line with IR(ME)R principles. A pragmatic interval of around three to six months is commonly used in practice to allow meaningful changes to accumulate and to reduce the influence of day-to-day variability, though you should confirm the appropriate timing with your provider. Comparing serial scans also allows assessment of whether weight loss has come predominantly from fat mass or from lean muscle mass, which is an important distinction when evaluating the quality of weight loss.

If you are considering a structured weight-management plan, discuss your DEXA results with your GP or a qualified clinician who can help interpret the findings in the context of your overall health and guide next steps.

Scientific References

1. Foundayo 17.2 mg film-coated tablets – Summary of Product Characteristics.
2. Mounjaro (tirzepatide) – EPAR Product Information.
3. When it is used — Bone density scan (DEXA scan).
4. Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity.
5. Guidance to the Ionising Radiation (Medical Exposure) Regulations 2017.
6. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
7. NG246 Appendix A1: Summary of evidence from surveillance (PH46).
8. BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups (PH46).
9. Does Visceral Fat Estimated by Dual-Energy X-ray Absorptiometry Independently Predict Cardiometabolic Risks in Adults?.
10. Liver in the analysis of body composition by dual-energy X-ray absorptiometry.
11. Visceral adiposity syndrome.
12. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
13. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238) – Recommendations.
14. Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Meta-analysis.
15. Effectiveness of a nurse-led phone intervention on body composition in adults with prediabetes and overweight/obesity: PREDIPHONE secondary analysis.
16. The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat in individuals with overweight and obesity: a systematic review and pairwise and network meta-analyses.
17. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.
18. GLP-1 medicines for weight loss and diabetes: what you need to know.
19. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis.
20. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
21. Sarcopenia and Sarcopenic Obesity and Mortality Among Older Adults.
22. Impact of body composition on clinical outcomes in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
23. Analysis of the efficacy of metabolic and bariatric surgery on sarcopenic obesity: a systematic review and meta-analysis.
24. Osteoporosis: risk assessment (NG259).
25. Machine learning allows robust classification of visceral fat in women with obesity using common laboratory metrics.

Frequently Asked Questions